TIMELY REVIEW Section Editor: Zubair Baloch, M.D.
Negative Computer-Imaged ThinPrep Pap Test and Positive Hybrid Capture2 HPV Co-Testing Results: A Quality Assurance Review Rema Rao, M.D., MIAC,* David Molina, M.D., Allison M. Halligan, M.S., Behzad Vakil, S.C.T. (ASCP), Susan A. Alperstein, S.C.T. (ASCP), and Rana S. Hoda, M.D., FIAC,
Women 30 years of age with negative (2) Pap tests and positive (1) HPV co-test results have a higher prevalence and cumulative risk of developing high-grade cervical intraepithelial neoplasia (CIN 21). Thus, the current management in these women is to repeat co-test in 12 months or immediate reflex genotyping for HPV16 or HPV 16/18. If genotyping is not an option, timely quality assurance (QA) rescreen of such Pap tests may be a valuable alternative. All ThinPrep Pap tests (TPPT) interpreted as negative for intra epithelial lesion (NILM) or NILM with reactive cellular changes (NILM/RCC) and a (1) high-risk HPV [Hybrid Capture 2 (HC2), Qiagen, Hilden, Germany] co-test result over a 45-month period (10/2009-06/2013) underwent monthly QA review. The TPPT were screened by the TP Imaging System [TIS, Hologic Inc., Bedford, MA]. Twenty five thousand six hundred and seventy five (18%) NILM and NILM/RCC TPPT of a total of 141,548 TPPT underwent HPV co-test. HPV test was
(1) in 2,300 (8.9%) TPPT cases. HPV (1) cases by age group were
Negative Computer-Imaged ThinPrep Pap Test and Positive Hybrid Capture2 HPV Co-Testing Results: A Quality Assurance Review Rema Rao, M.D., MIAC,* David Molina, M.D., Allison M. Halligan, M.S., Behzad Vakil, S.C.T. (ASCP), Susan A. Alperstein, S.C.T. (ASCP), and Rana S. Hoda, M.D., FIAC,
Women 30 years of age with negative (2) Pap tests and positive (1) HPV co-test results have a higher prevalence and cumulative risk of developing high-grade cervical intraepithelial neoplasia (CIN 21). Thus, the current management in these women is to repeat co-test in 12 months or immediate reflex genotyping for HPV16 or HPV 16/18. If genotyping is not an option, timely quality assurance (QA) rescreen of such Pap tests may be a valuable alternative. All ThinPrep Pap tests (TPPT) interpreted as negative for intra epithelial lesion (NILM) or NILM with reactive cellular changes (NILM/RCC) and a (1) high-risk HPV [Hybrid Capture 2 (HC2), Qiagen, Hilden, Germany] co-test result over a 45-month period (10/2009-06/2013) underwent monthly QA review. The TPPT were screened by the TP Imaging System [TIS, Hologic Inc., Bedford, MA]. Twenty five thousand six hundred and seventy five (18%) NILM and NILM/RCC TPPT of a total of 141,548 TPPT underwent HPV co-test. HPV test was
(1) in 2,300 (8.9%) TPPT cases. HPV (1) cases by age group were
